Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 93INDUSTRY 34NIH 12NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 265Leukemia 183Carcinoma, Non-Small-Cell Lung 168Lymphoma 159Lung Neoplasms 148Prostatic Neoplasms 134Precursor Cell Lymphoblastic Leukemia-Lymphoma 130Ovarian Neoplasms 117Colorectal Neoplasms 115Sarcoma 108Central Nervous System Neoplasms 107Head and Neck Neoplasms 98Leukemia, Myeloid, Acute 95Multiple Myeloma 93Squamous Cell Carcinoma of Head and Neck 83Rectal Neoplasms 77Colonic Neoplasms 71Uterine Cervical Neoplasms 65Neoplasm Metastasis 65Neuroblastoma 64Carcinoma, Ovarian Epithelial 64Brain Neoplasms 64Neoplasms 63Fallopian Tube Neoplasms 62Lymphoma, Large B-Cell, Diffuse 61Melanoma 59Astrocytoma 59Leukemia, Lymphocytic, Chronic, B-Cell 56Burkitt Lymphoma 56Hodgkin Disease 55

Interventions

Temozolomide 1Etoposide 1Cisplatin 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Carcinoma, Neuroendocrine × Clear all
NCT02595424 2026-05-01

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
67 enrolled 13 charts
Endocrine

Somatostatinoma, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡